他指出，研究结果还表明，患者的一个子集可能表现出更显著的效应。这在无进展生存期（PFS）的结果中能明显地看出来。

The findings also suggest that a subset of patients may be achieving a more significant benefit. This is apparent in the results of PFS, he pointed out.

youdao

即使无进展生存期的中位数看起来不相同，风险比是0.6。“因为存在一个重要的患者子集通过一个重要途径受益。”

Even though the median in PFS doesn't look different, the HR is 0.6 "because there is a significant patient subset who benefit in a significant way. ""

youdao